1-2 of 2
Sangeeta V Raje
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial

Carrie Turich Taylor, Eunhee Hwang, Tina Hinnershitz, Eugeny Mefyod, Sangeeta V Raje, John Teeter, Travis Gould, Andrew Palladino
Journal: Blood
Blood (2024) 144 (Supplement 1): 1210.
https://doi.org/10.1182/blood-2024-205843
Published: 2024
Journal Articles

A Fixed (Weight-independent) Subcutaneous Once-Weekly Dose for Marstacimab, an Anti-TFPI Monoclonal Antibody for the Prophylactic Treatment of Hemophilia Α and B

Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, Sangeeta V Raje
Journal: Blood
Blood (2024) 144 (Supplement 1): 1215.
https://doi.org/10.1182/blood-2024-199766
Published: 2024